FHTX — Foghorn Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1822462 ·
Last close
$1.83
Market Cap
$109.73M
52W High
$7.61
52W Low
$1.73
ADV30
753,796
Next earnings
2026-11-09
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 83,543,000 — 58,911,000 58,150,000 190,952,000 80,302,000 205,036,000
Jun 2026 16,072,000 — -8,805,000 -7,191,000 203,393,000 68,080,000 284,434,000
Mar 2026 3,267,000 — -21,573,000 -19,875,000 222,167,000 87,663,000 298,575,000
Dec 2025 9,247,000 — -19,596,000 -21,664,000 198,103,000 80,876,000 306,603,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-83,624,000
Investing CF
$16,735,000
Financing CF
$56,607,000
CapEx
$-57,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.16
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-601,383,000
Inventory
—
Receivables
—
ST Investments
$75,920,000
EBIT TTM
$8,937,000
Pretax Income TTM
$9,420,000
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$112,129,000
EBITDA
$10,422,000
Free Cash Flow
$-26,355,376
Enterprise Value
$11,768,686
Total Cash
$156,222,000
Total Debt
$43,868,000
Shares Out
59,962,650
Trailing EPS
$0.09
Book Value
$-0.23
ROE
—
ROA
2.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 30,909,000 -82,107,000 -74,283,000 198,103,000 306,603,000 -108,500,000 -86,099,000
Dec 2024 22,602,000 -100,285,000 -86,620,000 283,982,000 329,510,000 -45,528,000 -100,406,000
Dec 2023 34,155,000 -107,906,000 -98,426,000 285,916,000 363,106,000 -77,190,000 -118,106,000
Dec 2022 19,228,000 -117,137,000 -108,882,000 404,883,000 404,771,000 112,000 193,612,000

TTM Snapshot

Revenues TTM
$36,739,000
NetIncome TTM
$-64,579,000
OpCashFlow TTM
—
Assets (Latest)
$203,393,000
Forward EPS
$-1.11

Max Pain — expiry 2026-12-18

max pain strike: $2.50 · spot: $1.79 · call oi: 428 · put oi: 746
Expected Move to 2026-12-18: ±$0.73 (40.50%) — implied range $1.06 – $2.52 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AKBA Akebia Therapeutics, Inc. $111.18M $0.40 —
SCNX Scienture Holdings, Inc. $113.34M $2.76 —
NRXP NRX Pharmaceuticals, Inc. $106.07M $2.45 —
ORGO Organogenesis Holdings Inc. $105.35M $0.81 —
UPB Upstream Bio, Inc. $115.10M $2.10 —

News headlines (Yahoo Finance, 1h cache)

Foghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat Estimates
2026-11-09 12:40 · Yahoo
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
2026-11-09 12:22 · Yahoo
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
2026-11-03 12:00 · Yahoo
Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-28 13:00 · Yahoo
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
2026-10-22 01:24 · Yahoo
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
2026-10-02 18:12 · Yahoo
Sector Update: Healthcare Stocks Fall Late Afternoon
2026-10-01 19:57 · Yahoo
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
2026-10-01 19:51 · Yahoo
Top Midday Decliners
2026-10-01 18:44 · Yahoo
Lilly, Foghorn part ways; Wave’s FDA-approved plans
2026-10-01 16:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.